Skip to content
Screener

Oruka Therapeutics, Inc. ORKA Return on invested capital

Return on invested capital at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
16.7%+8.4pp
Eli Lilly logo
Eli LillyLLY
39.7%+10.3pp
Johnson & Johnson logo
Johnson & JohnsonJNJ
19.2%+1.3pp
Amgen logo
AmgenAMGN
14.8%+3.6pp
AbbVie logo
AbbVieABBV
17.1%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
-199.6%+598pp

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.94B+1,017%
Enterprise value$5.89B+1,158%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Calculated from Oruka Therapeutics, Inc.’s reported figures.

Based on trailing twelve months.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026. Open the filing →

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769

FAQ

What is Oruka Therapeutics, Inc.'s return on invested capital?
Oruka Therapeutics, Inc. (ORKA) reported return on invested capital of -37% in Q1 2026.
What does return on invested capital mean?
Net operating profit after tax (operating income taxed at the effective rate) divided by average invested capital (debt plus equity minus cash). Measures the after-tax return on all capital put to work in the business, independent of capital structure.

Ask your AI about Oruka Therapeutics, Inc.'s return on invested capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude